Pharma Focus Europe

Adragos Pharma acquires Clinigen's development unit, Lamda Laboratories

Tuesday, March 21, 2023

Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limited to acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers.

Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreement, Lamda will continue to provide services for Clinigen Limited.

The Athens site, a mere 15 minute drive from the airport, is fully equipped with state of the art equipment including the handling of potent drugs, established Quality systems and a proven track record of delivering complex developments on time for customers.

A highly experienced management team and well-trained staff will continue to focus on complex product development for growing markets in Europe, Japan, and North America. Lamda will offer an expanded range of pharmaceutical development, regulatory affairs and supply chain management services for a wide range of dosage forms including complex and high potent oral solids, differentiated oral liquids, injectables and topical medicines. As part of the transaction, Adragos secures royalty streams for products stemming from previous co-developments.

David Bryant, Interim CEO of Clinigen Limited states: "We are pleased to have found in Adragos Pharma a trusted partner to build on the success story of Lamda with its great team taking it to the next level while also continuing to support Clinigen as we focus on providing high-value services to the biopharma industry.”

Dr. Andreas Raabe, CEO of Adragos Pharma commended the “impressive track record and professional service mindset at Lamda”. He noted that “Lamda combines differentiated product development capabilities with substantial scale, an essential combination for our international group.”

The exact terms of the transaction will not be disclosed. Completion of the transaction is subject to customary conditions precedent.

 

Source: realwire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva